

### References

Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, Pierschbacher MD, del Zoppo GJ. Integrin IIb3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. *Stroke*. 2000;31:1402-10.

Ahmed AH, Oswald RE. Piracetam defines a new binding site for allosteric modulators of  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. *Journal of medicinal chemistry*. 2010 Feb 17;53(5):2197-203.

Alagem N, Dvir M, Reuveny E. Mechanism of Ba<sup>2+</sup> block of a mouse inwardly rectifying K<sup>+</sup> channel: differential contribution by two discrete residues. *The Journal of physiology*. 2001 Jul;534(2):381-93.

Arepalli SK, Tripathi H, Vyas VK, Jain S, Suman SK, Pyare R, Singh SP. Influence of barium substitution on bioactivity, thermal and physico-mechanical properties of bioactive glass. *Materials Science and Engineering: C*. 2015 Apr 1;49:549-59.

Baino F, Hamzehlou S, Kargozar S. Bioactive glasses: where are we and where are we going?. *Journal of functional biomaterials*. 2018 Mar;9(1):25.

Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic stroke. *American Journal of Cardiovascular Drugs*. 2013 Feb;13(1):57-69.

Barkat K, Ahmad M, Minhas MU, Malik MZ, Sohail M. Development of a simple chromatographic method for the determination of piracetam in human plasma and its pharmacokinetic evaluation. *Drug research*. 2014 Jul;64(07):384-8.

## References

---

- Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski HE. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. *stroke*. 1986 May;17(3):472-6.
- Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. *Stroke*. 1996 Sep;27(9):1616-22.
- Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. *Brain research*. 1996 Nov 11;739(1-2):88-96.
- Belayev L, Khoutorova L, Deisher TA, Belayev A, Busto R, Zhang Y, Zhao W, Ginsberg MD. Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats. *Stroke*. 2003 Mar 1;34(3):758-63.
- Belayev L, Khoutorova L, Deisher TA, Belayev A, Busto R, Zhang Y, Zhao W, Ginsberg MD. Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats. *Stroke*. 2003 Mar 1;34(3):758-63.
- Berti R, Williams AJ, Moffett JR, Hale SL, Velarde LC, Elliott PJ, Yao C, Dave JR, Tortella FC. Quantitative Real-Time RT—PCR Analysis of Inflammatory Gene Expression Associated with Ischemia—Reperfusion Brain Injury. *Journal of Cerebral Blood Flow & Metabolism*. 2002 Sep;22(9):1068-79.
- Born GV, Wehmeier A. Inhibition of platelet thrombus formation by chlorpromazine acting to diminish haemolysis. *Nature*. 1979 Nov;282(5735):212.
- Brass LF. Thrombin and platelet activation. *Chest*. 2003 Sep 1;124(3):18S-25S.

## References

---

Brown P, Steiger MJ, Thompson PD, Rothwell JC, Day BL, Salama M, Waegemans T, Marsden CD. Effectiveness of piracetam in cortical myoclonus. *Movement disorders: official journal of the Movement Disorder Society*. 1993;8(1):63-8.

Bunting S, Di Silvio L, Deb S, Hall S. Bioresorbable glass fibres facilitate peripheral nerve regeneration. *Journal of Hand Surgery*. 2005 Jun;30(3):242-7.

Cacciotti I, Lombardi M, Bianco A, Ravaglioli A, Montanaro L. Sol-gel derived 45S5 bioglass: synthesis, microstructural evolution and thermal behaviour. *Journal of Materials Science: Materials in Medicine*. 2012 Aug 1;23(8):1849-66.

Calliauw L, Marchau M. Clinical trial of piracetam in disorders of consciousness due to head injury. *Acta Anaesthesiologica Belgica*. 1975 Apr;26(1):51-60.

Campbell BC, Donnan GA, Lees KR, et al. Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. *Lancet Neurol* 2015; 14:846.

Caplan LR. *Navigating the Complexities of Stroke*, American Academy of Neurology and Oxford University Press, New York 2013.

Caplan LR. *Stroke*, American Academy of Neurology and Demos Publishers, New York 2006.

Cha JK, Jeon HW, Kang MJ. ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. *European journal of neurology*. 2008 Dec;15(12):1304-8.

Chia NH, Leyden JM, Newbury J, et al. Determining the Number of Ischemic Strokes Potentially Eligible for Endovascular Thrombectomy: A Population-Based Study. *Stroke* 2016; 47:1377.

## References

---

Choudhri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES, Kottirsch G, Pinsky DJ. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. *The Journal of clinical investigation*. 1998 Oct 1;102(7):1301-10.

Cohen DL, Kearney R, Griffiths M, et al. Around 9% of patients with ischaemic stroke are suitable for thrombectomy. *BMJ* 2015; 351:h4607.

Coyle P. Middle cerebral artery occlusion in the young rat. *Stroke*. 1982 Nov;13(6):855-9.

Day RM, Boccaccini AR, Shurey S, Roether JA, Forbes A, Hench LL, Gabe SM. Assessment of polyglycolic acid mesh and bioactive glass for soft-tissue engineering scaffolds. *Biomaterials*. 2004 Dec 1;25(27):5857-66.

Day RM. Bioactive glass stimulates the secretion of angiogenic growth factors and angiogenesis in vitro. *Tissue engineering*. 2005 May 1;11(5-6):768-77.

De Deyn PP, De Reuck J, Deberdt W, Vlietinck R, Orgogozo JM. Treatment of acute ischemic stroke with piracetam. *Stroke*. 1997 Dec;28(12):2347-52.

De Reuck J, Van Vleymen B. The clinical safety of high-dose piracetam-its use in the treatment of acute stroke. *Pharmacopsychiatry*. 1999 Mar;32(S 1):33-7.

De Ryck M, Van Reempts J, Borgers M, Wauquier A, Janssen PA. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. *Stroke*. 1989 Oct;20(10):1383-90.

Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. *Pathophysiology*. 2010 Jun 1;17(3):197-218.

## References

---

- Del Zoppo GJ. The role of platelets in ischemic stroke. *Neurology*. 1998 Sep 1;51(3 Suppl 3):S9-14.
- Deng Y, Xiong D, Yin C, Liu B, Shi J, Gong Q. Icariside II protects against cerebral ischemia–reperfusion injury in rats via nuclear factor- $\kappa$ B inhibition and peroxisome proliferator-activated receptor up-regulation. *Neurochemistry international*. 2016 Jun 1;96:56-61.
- Depresseux JC, Salmon E, Sadzot B, Cornette M, Franck G. Evaluation of the effect of piracetam on CBF and CMRO<sub>2</sub> in acute stroke patients using PET and 15-oxygen. *J. Libbey Eurotext*. 1986:579-83.
- Dhurat R, Sukesh MS. Principles and methods of preparation of platelet-rich plasma: a review and author's perspective. *Journal of cutaneous and aesthetic surgery*. 2014 Oct;7(4):189.
- Doheny MH, O'CONNELL MT, Patsalos PN. A High-performance Liquid-chromatographic Microanalytical Procedure for the Rapid Estimation of Piracetam in Plasma or Cerebrospinal Fluid. *Journal of pharmacy and pharmacology*. 1996 May;48(5):514-6.
- Durukan A, Marinkovic I, Strbian D, Pitkonen M, Pedrono E, Soenne L, Abo-Ramadan U, Tatlisumak T. Post-ischemic blood–brain barrier leakage in rats: one-week follow-up by MRI. *Brain research*. 2009 Jul 14;1280:158-65.
- Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. *Pharmacology Biochemistry and Behavior*. 2007 May 1;87(1):179-97.

## References

---

- El-Fiqi A, Kim TH, Kim M, Eltohamy M, Won JE, Lee EJ, Kim HW. Capacity of mesoporous bioactive glass nanoparticles to deliver therapeutic molecules. *Nanoscale*. 2012;4(23):7475-88.
- Ezzati M, Vander Hoorn S, Rodgers A, Lopez AD, Mathers CD, Murray CJ, Comparative Risk Assessment Collaborating Group. Estimates of global and regional potential health gains from reducing multiple major risk factors. *The Lancet*. 2003 Jul 26;362(9380):271-80.
- Fahlenkamp AV, Coburn M, de Prada A, Gereitzig N, Beyer C, Haase H, Rossaint R, Gempt J, Ryang YM. Expression analysis following argon treatment in an in vivo model of transient middle cerebral artery occlusion in rats. *Medical gas research*. 2014 Dec;4(1):11.
- Fan W, Wu C, Han P, Zhou Y, Xiao Y. Porous Ca–Si-based nanospheres: A potential intracanal disinfectant-carrier for infected canal treatment. *Materials Letters*. 2012 Aug 15;81:16-9.
- FDA U. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2002.
- Fitridge R, Thompson M. Mechanisms of vascular disease: a reference book for vascular specialists. University of Adelaide Press; 2011.
- Freedman JE. Oxidative stress and platelets. *Arteriosclerosis, thrombosis, and vascular biology*. 2008 Mar 1;28(3):s11-6.
- Furlan AJ. Endovascular therapy for stroke--it's about time. *N Engl J Med* 2015; 372:2347.
- Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. *Circulation*. 1990 Sep;82(3 Suppl):II47-59.

## References

---

- Gandin C, Widmann C, Lazdunski M, Heurteaux C. MLC901 favors angiogenesis and associated recovery after ischemic stroke in mice. *Cerebrovascular Diseases*. 2016;42(1-2):139-54.
- Garcia JH, Liu KF, Yoshida Y, Chen S, Lian J. Brain microvessels: factors altering their patency after the occlusion of a middle cerebral artery (Wistar rat). *The American journal of pathology*. 1994 Sep;145(3):728.
- Gobert JG, Baltes EL. Availability and plasma clearance of piracetam in man. *Il Farmaco; edizione pratica*. 1977 Feb;32(2):83.
- Gorustovich AA, Roether JA, Boccaccini AR. Effect of bioactive glasses on angiogenesis: a review of in vitro and in vivo evidences. *Tissue Engineering Part B: Reviews*. 2009 Dec 3;16(2):199-207.
- Gouliarov AH, Senning A. Piracetam and other structurally related nootropics. *Brain research reviews*. 1994 May 1;19(2):180-222.
- Greenhalgh AD, Galea J, Denes A, Tyrrell PJ, Rothwell NJ. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. *British journal of pharmacology*. 2010 May;160(1):153-9.
- Greenspan D, West J, Lee S, Meyers J, Diamond M, inventors; Greenspan David C., West Jon K., Meyers James L., assignee. Anti-inflammatory and antimicrobial uses for bioactive glass compositions. United States patent application US 10/865,636. 2004 Nov 18.
- Grotemeyer KH, Evers S, Fischer M, Husstedt IW. Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. *Journal of the neurological sciences*. 2000 Dec 1;181(1-2):65-72.

## References

---

Guo Q, Wang G, Namura S. Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice. *Journal of Cerebral Blood Flow & Metabolism*. 2010 Jan;30(1):70-8.

Harukuni I, Bhardwaj A. Mechanisms of brain injury after global cerebral ischemia. *Neurologic clinics*. 2006 Feb 1;24(1):1-21.

Hossmann KA. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. *Journal of Cerebral Blood Flow & Metabolism*. 2012 Jul;32(7):1310-6.

Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G. Behavioral tests after intracerebral hemorrhage in the rat. *Stroke*. 2002 Oct 1;33(10):2478-84.

Huber W. The role of piracetam in the treatment of acute and chronic aphasia. *Pharmacopsychiatry*. 1999 Mar;32(S 1):38-43.

Hutton C, Caplan LR. *Striking Back at Stroke: A Doctor-Patient Journal*, Dana Press, New York 2003.

Hutton C. *After a Stroke: 300 Tips for Making Life Easier*, Demos, New York 2005.

Jadhav AP, Desai SM, Kenmuir CL, et al. Eligibility for Endovascular Trial Enrollment in the 6- to 24-Hour Time Window: Analysis of a Single Comprehensive Stroke Center. *Stroke* 2018; 49:1015.

Jarrott DM, Domer FR. A gerbil model of cerebral ischemia suitable for drug evaluation. *Stroke*. 1980 Mar;11(2):203-9.



## References

---

Josephson SA, Kamel H. The Acute Stroke Care Revolution: Enhancing Access to Therapeutic Advances. *JAMA* 2018; 320:1239.

Karacostas D, Doskas T, Artemis N, Vadicolias K, Milonas I. Beneficial effect of piracetam monotherapy on post-ischaemic palatal myoclonus. *Journal of international medical research*. 1999 Jul;27(4):201-5.

Köhrmann M, Schellinger PD. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro MR imaging. *Radiology*. 2009 Jun;251(3):627-33.

Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson LM, Truelsen T, O'Donnell M. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. *The Lancet Global Health*. 2013 Nov 1;1(5):e259-81.

Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. *Acta neuropathologica*. 1985 Jun 1;68(2):122-9.

Landgraf L, Nordmeyer D, Schmiel P, Gao Q, Ritz S, Gebauer JS, Graß S, Diabaté S, Treuel L, Graf C, Rühl E. Validation of weak biological effects by round robin experiments: cytotoxicity/biocompatibility of SiO<sub>2</sub> and polymer nanoparticles in HepG2 cells. *Scientific reports*. 2017 Jun 28;7(1):4341.

Latchaw RE, Alberts MJ, Lev MH, Connors JJ, Harbaugh RE, Higashida RT, Hobson R, Kidwell CS, Koroshetz WJ, Mathews V, Villablanca P. Recommendations for imaging of

## References

---

acute ischemic stroke: a scientific statement from the American Heart Association. *Stroke*. 2009 Nov 1;40(11):3646-78.

Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood–brain barrier disruption in human focal brain ischemia. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 2004 Oct;56(4):468-77.

Li J, He J, Du Y, Cui J, Ma Y, Zhang X. Electroacupuncture improves cerebral blood flow and attenuates moderate ischemic injury via Angiotensin II its receptors-mediated mechanism in rats. *BMC complementary and alternative medicine*. 2014 Dec;14(1):441.

Li Y, Lu Y, Hu J, Gong Z, Yang W, Wang A, Zheng J, Liu T, Chen T, Hu J, Mi L. Pharmacokinetic comparison of scutellarin and paeoniflorin in sham-operated and middle cerebral artery occlusion ischemia and reperfusion injury rats after intravenous administration of xin-shao formula. *Molecules*. 2016;21(9):1191.

Liu T, Zhang T, Yu H, Shen H, Xia W. Adjudin protects against cerebral ischemia reperfusion injury by inhibition of neuroinflammation and blood-brain barrier disruption. *Journal of neuroinflammation*. 2014 Dec;11(1):107.

Liu YZ, Li Y, Yu XB, Liu LN, Zhu ZA, Guo YP. Drug delivery property, bactericidal property and cytocompatibility of magnetic mesoporous bioactive glass. *Materials Science and Engineering: C*. 2014 Aug 1;41:196-205.

Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. *stroke*. 1989 Jan;20(1):84-91.

## References

---

Mao C, Chen X, Hu Q, Miao G, Lin C. Acute toxicity and in vivo biodistribution of monodispersed mesoporous bioactive glass spheres in intravenously exposed mice. *Materials Science and Engineering: C*. 2016 Jan 1;58:682-91.

Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. *The Journal of clinical investigation*. 1997 Mar 15;99(6):1351-60.

Martin LJ, Al-Abdulla NA, Brambrink AM, Kirsch JR, Sieber FE, Portera-Cailliau C. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. *Brain research bulletin*. 1998 Jul 1;46(4):281-309.

Moldavkin GM, Voronina TA, Neznamov GG, Maletova OK, Eliava NV. Participation of GABA--benzodiazepine receptor complex in the anxiolytic effect of piracetam. *Ekspierimental'naia i klinicheskaia farmakologiiia*. 2006;69(3):7-9.

Muddana NR, Benade V, Paliwal P, Muppidi AB, Subramanian R, Chillakur M, Kandikere V, Bhyrapuneni G, Nirogi R. Neuro-pharmacokinetics based prediction of p-glycoprotein liability in early drug discovery. In *DRUG METABOLISM REVIEWS* 2014 Jan 1 (Vol. 45, pp. 111-112). Telephone House, 69-77 Paul Street, London Ec2a 4lq, England: Informa Healthcare.

Muddana NR, Paliwal P, Aleti RR, Bhyrapuneni G, Nirogi R. Pharmacokinetics and brain penetration of donepezil after intranasal, oral, intravenous administration using rat as model- a comparison study. In *DRUG METABOLISM REVIEWS* 2015 Nov 20 (Vol. 47, pp. 227-

## References

---

227). 4 Park Square, Milton Park, Abingdon Ox14 4rn, Oxon, England: Taylor & Francis Ltd.

Muir KW, Buchan A, von Kummer R, Rother J, Baron JC. Imaging of acute stroke. *The Lancet Neurology*. 2006 Sep 1;5(9):755-68.

Nalbandian RM, Henry RL, Burek CL, Diglio CA, Goldman AI, Taylor GW, Hoffman WH. Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam. *American journal of hematology*. 1983 Sep;15(2):147-51.

Nicotera P, Lipton SA. Excitotoxins in neuronal apoptosis and necrosis. *Journal of Cerebral Blood Flow & Metabolism*. 1999 Jun;19(6):583-91.

Nirogi R, Ajjala DR, Kandikere V, Pantangi HR, Jonnala MR, Bhyrapuneni G, Muddana NR, Vurimindi H. LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. *Biomedical Chromatography*. 2013 Nov;27(11):1431-7.

Nishimori H, Kondoh M, Isoda K, Tsunoda SI, Tsutsumi Y, Yagi K. Histological analysis of 70-nm silica particles-induced chronic toxicity in mice. *European Journal of Pharmaceutics and Biopharmaceutics*. 2009 Aug 1;72(3):626-9.

Paliwal P, Chauhan G, Gautam D, Dash D, Patne SC, Krishnamurthy S. Indole-3-carbinol improves neurobehavioral symptoms in a cerebral ischemic stroke model. *Naunyn-Schmiedeberg's archives of pharmacology*. 2018 Jun 1;391(6):613-25.

Paliwal P, Dash D, Krishnamurthy S. Pharmacokinetic study of piracetam in focal cerebral ischemic rats. *European journal of drug metabolism and pharmacokinetics*. 2018 Apr 1;43(2):205-13.

## References

---

- Paliwal P, Kumar AS, Tripathi H, Singh SP, Patne SC, Krishnamurthy S. Pharmacological application of barium containing bioactive glass in gastro-duodenal ulcers. *Materials Science and Engineering: C*. 2018 Nov 1;92:424-34.
- Palomeras Soler E, Casado Ruiz V. Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: similarities and differences. *Current cardiology reviews*. 2010 Aug 1;6(3):138-49.
- Pandian JD, Sudhan P. Stroke epidemiology and stroke care services in India. *Journal of stroke*. 2013 Sep;15(3):128.
- Pillai DR, Dittmar MS, Baldaranov D, Heidemann RM, Henning EC, Schuierer G, Bogdahn U, Schlachetzki F. Cerebral ischemia–reperfusion injury in rats—A 3 T MRI study on biphasic blood–brain barrier opening and the dynamics of edema formation. *Journal of Cerebral Blood Flow & Metabolism*. 2009 Nov;29(11):1846-55.
- Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, Connolly ES, Huang J, Kiss S, Zhang Y, Choudhri TF. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. *The Journal of clinical investigation*. 2002 Apr 15;109(8):1031-40.
- Platt D, Horn J, Summa JD, Schmitt-Rüth R, Kauntz J, Krönert E. On the efficacy of piracetam in geriatric patients with acute cerebral ischemia: a clinically controlled double-blind study. *Archives of gerontology and geriatrics*. 1993 Mar 1;16(2):149-64.
- Sahu K, Shaharyar M, Siddiqui AA. Effect of Morin on pharmacokinetics of Piracetam in rats, in vitro enzyme kinetics and metabolic stability assay using rapid UPLC method. *Drug testing and analysis*. 2013 Jul;5(7):581-8.

## References

---

Saletu B, Hitzemberger G, Grünberger J, Anderer P, Zyhlarz G, Linzmayer L, Rameis H. Double-blind, placebo-controlled, pharmacokinetic and-dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man. *International journal of clinical pharmacology and therapeutics*. 1995 May;33(5):249-62.

Sarshoori JR, Asadi MH, Mohammadi MT. Neuroprotective effects of crocin on the histopathological alterations following brain ischemia-reperfusion injury in rat. *Iranian journal of basic medical sciences*. 2014 Nov;17(11):895.

Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 2007 May;61(5):396-402.

Shankar H, Kahner BN, Prabhakar J, Lakhani P, Kim S, Kunapuli SP. G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases. *Blood*. 2006 Nov 1;108(9):3027-34.

Sheth KN, Smith EE, Grau-Sepulveda MV, et al. Drip and ship thrombolytic therapy for acute ischemic stroke: use, temporal trends, and outcomes. *Stroke* 2015; 46:732.

Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D. Characterization of antiplatelet properties of silver nanoparticles. *ACS nano*. 2009 May 4;3(6):1357-64.

Sicard KM, Fisher M. Animal models of focal brain ischemia. *Experimental & translational stroke medicine*. 2009 Dec 1;1(1):7.

Stahlhut L, Grottemeyer KH, Husstedt IW, Evers S. The impact of stroke on cognitive processing—a prospective event-related potential study. *Journal of the neurological sciences*. 2014 Apr 15;339(1-2):157-63.

## References

---

Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, Abo-Ramadan U, Tatlisumak T. The blood–brain barrier is continuously open for several weeks following transient focal cerebral ischemia. *Neuroscience*. 2008 Apr 22;153(1):175-81.

Sui B, Zhong G, Sun J. Drug-loadable Mesoporous Bioactive Glass Nanospheres: Biodistribution, Clearance, BRL Cellular Location and Systemic Risk Assessment via <sup>45</sup>Ca Labelling and Histological Analysis. *Scientific reports*. 2016 Sep 15;6:33443.

Tacconi MT, Wurtman RJ. Piracetam: physiological disposition and mechanism of action. *Advances in neurology*. 1986;43:675-85.

Traystman RJ. Animal models of focal and global cerebral ischemia. *ILAR journal*. 2003 Jan 1;44(2):85-95.

Tripathi A, Paliwal P, Krishnamurthy S. Piracetam attenuates LPS-induced neuroinflammation and cognitive impairment in rats. *Cellular and molecular neurobiology*. 2017 Nov 1;37(8):1373-86.

Tsai MJ, Tsai SK, Huang MC, Liou DY, Huang SL, Hsieh WH, Huang WC, Huang SS, Cheng H. Acidic FGF promotes neurite outgrowth of cortical neurons and improves neuroprotective effect in a cerebral ischemic rat model. *Neuroscience*. 2015 Oct 1;305:238-47.

Vallet-Regí M, Ruiz-Hernández E. Bioceramics: from bone regeneration to cancer nanomedicine. *Advanced Materials*. 2011 Nov 23;23(44):5177-218.

Venturini CG, Bruinsmann FA, Oliveira CP, Contri RV, Pohlmann AR, Guterres SS. Vegetable oil-loaded nanocapsules: innovative alternative for incorporating drugs for

## References

---

parenteral administration. *Journal of nanoscience and nanotechnology*. 2016 Feb 1;16(2):1310-20.

Wang X, Zhu J, Xu R, Yang X, Wu H, Lin D, Ye F, Hu L. Determination of piracetam in rat plasma by LC–MS/MS and its application to pharmacokinetics. *Biomedical Chromatography*. 2010 Oct;24(10):1108-12.

Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood–brain barrier disruption. *Stroke*. 2004 Nov 1;35(11\_suppl\_1):2659-61.

Weaver J, Liu KJ. Does normobaric hyperoxia increase oxidative stress in acute ischemic stroke? A critical review of the literature. *Medical gas research*. 2015 Dec;5(1):11.

Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *The Lancet*. 2013 Nov 9;382(9904):1575-86.

Winblad B. Piracetam: a review of pharmacological properties and clinical uses. *CNS drug reviews*. 2005 Mar;11(2):169-82.

Winnicka K, Tomasiak M, Bielawska A. Piracetam-an old drug with novel properties. *Acta Pol Pharm*. 2005 Sep;62(5):405-9.

Wintermark M, Rowley HA, Lev MH. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro CT. *Radiology*. 2009 Jun;251(3):619-26.



## References

---

Wu C, Fan W, Chang J. Functional mesoporous bioactive glass nanospheres: synthesis, high loading efficiency, controllable delivery of doxorubicin and inhibitory effect on bone cancer cells. *Journal of Materials Chemistry B*. 2013;1(21):2710-8.

Wu J, Li Q, Wang X, Yu S, Li L, Wu X, Chen Y, Zhao J, Zhao Y. Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway. *PloS one*. 2013 Mar 28;8(3):e59843.

Wustmann CH, Fischer HD, Schmidt J. The effect of piracetam on posthypoxic dopamine release inhibition. *Acta biologica et medica Germanica*. 1982;41(7-8):729-32.

Yang F, Jiang W, Bai Y, Han J, Liu X, Zhang G, Zhao G. Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial. *BMC neurology*. 2015 Dec;15(1):195.

Yeo SH, Lim ZJ, Mao J, Yau WP. Effects of central nervous system drugs on recovery after stroke: a systematic review and meta-analysis of randomized controlled trials. *Clinical drug investigation*. 2017 Oct 1;37(10):901-28.

Zhu H, Qian Z, He F, Liu M, Pan L, Zhang Q, Tang Y. Novel pharmacokinetic studies of the Chinese formula Huang-Lian-Jie-Du-Tang in MCAO rats. *Phytomedicine*. 2013 Jul 15;20(10):767-74.

## List of Publication from Thesis

---

### List of Publication from Thesis

**Paliwal P**, Dash D, Krishnamurthy S. Pharmacokinetic study of piracetam in focal cerebral ischemic rats. European journal of drug metabolism and pharmacokinetics. 2018 Apr 1;43(2):205-13. (Impact Factor 1.36)

**Paliwal P**, Kumar AS, Tripathi H, Singh SP, Patne SC, Krishnamurthy S. Pharmacological application of barium containing bioactive glass in gastro-duodenal ulcers. Materials Science and Engineering: C. 2018 Nov 1; 92: 424-434. (Impact Factor 5.08)